Monday, 23 September 2019

JHL Biotech raises $106M in pre-IPO funding

30 May 2018 | News

JHL will allocate its new capital to support clinical trials and further development of its biosimilar portfolio.

Image credit- invictusnews.com

Image credit- invictusnews.com

JHL Biotech, a Taiwan developer of cheaper alternatives to patent-protected biological drugs, has raised $106 million from a convertible bond issue, ahead of its planned Hong Kong initial public offering (IPO) aiming to raise some $250 million.

JHL will allocate its new capital to support clinical trials and further development of its biosimilar portfolio. Earlier this year, JHL completed a voluntary de-listing of its Taiwan shares, a transaction that allowed shareholders to retain ownership of their holdings.

JHL is among at least two other non-mainland companies that have been preparing or mulling to tap the Hong Kong stock exchange’s equity-raising channel that was recently broadened to allow pre-revenue biotechnology firms to list for the first time.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls